Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 이정연 | * |
dc.contributor.author | 강지은 | * |
dc.contributor.author | 김명규 | * |
dc.date.accessioned | 2021-05-17T16:31:11Z | - |
dc.date.available | 2021-05-17T16:31:11Z | - |
dc.date.issued | 2021 | * |
dc.identifier.issn | 2075-4426 | * |
dc.identifier.other | OAK-29214 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/257352 | - |
dc.description.abstract | This study aims to evaluate potentially appropriate antiplatelet therapy in patients with chronic kidney disease. A systematic analysis was conducted to identify the clinical outcomes of available antiplatelet therapy regimens with enhanced platelet inhibition activity (intervention of 5 regimens) over the standard dose of clopidogrel-based dual antiplatelet therapy in patients with renal insufficiency. An electronic keyword search was performed on Pubmed, Embase, and Cochrane Library per PRISMA guidelines. We performed a prespecified net clinical benefit analysis (a composite of the rates of all-cause or cardiac-related death, myocardial infarction, major adverse cardiac outcomes, and minor and major bleeding), and included 12 studies. The intervention substantially lowered the incidence of all-cause mortality (RR 0.67; p = 0.003), major adverse cardiac outcomes (RR 0.79; p < 0.00001), and myocardial infarction (RR 0.28; p = 0.00007) without major bleeding (RR 1.14; p = 0.33) in patients with renal insufficiency, but no significant differences were noticed with cardiac-related mortality and stent thrombosis. The subgroup analysis revealed substantially elevated bleeding risk in patients with severe renal insufficiency or on hemodialysis (RR 1.68; p = 0.002). Our study confirmed that the intervention considerably enhances clinical outcomes in patients with renal insufficiency, however, a standard dose of clopidogrel-based antiplatelet therapy is favorable in patients with severe renal insufficiency. | * |
dc.language | English | * |
dc.publisher | MDPI | * |
dc.subject | acute coronary syndrome | * |
dc.subject | antiplatelet | * |
dc.subject | dual antiplatelet therapy | * |
dc.subject | chronic kidney disease | * |
dc.subject | hemodialysis | * |
dc.subject | clopidogrel resistance | * |
dc.subject | high on-treatment of platelet reactivity | * |
dc.title | P2Y12 Antiplatelet Choice for Patients with Chronic Kidney Disease and Acute Coronary Syndrome: A Systematic Review and Meta-Analysis | * |
dc.type | Review | * |
dc.relation.issue | 3 | * |
dc.relation.volume | 11 | * |
dc.relation.index | SCIE | * |
dc.relation.index | SCOPUS | * |
dc.relation.journaltitle | JOURNAL OF PERSONALIZED MEDICINE | * |
dc.identifier.doi | 10.3390/jpm11030222 | * |
dc.identifier.wosid | WOS:000633780400001 | * |
dc.identifier.scopusid | 2-s2.0-85103091858 | * |
dc.author.google | Park, Sohyun | * |
dc.author.google | Choi, Yeo Jin | * |
dc.author.google | Kang, Ji Eun | * |
dc.author.google | Kim, Myeong Gyu | * |
dc.author.google | Jung Geum, Min | * |
dc.author.google | Kim, So Dam | * |
dc.author.google | Rhie, Sandy Jeong | * |
dc.contributor.scopusid | 이정연(57191753089) | * |
dc.contributor.scopusid | 강지은(57155481300) | * |
dc.contributor.scopusid | 김명규(57193132066) | * |
dc.date.modifydate | 20240311140049 | * |